The development of effective pharmaceuticals often hinges on the availability and quality of specific chemical intermediates. Ethyl cis-4-amino-3-methoxypiperidine-1-carboxylate monohydrochloride, with its established CAS number 83863-71-2, is a prime example of such a critical compound, finding its primary utility as an intermediate in the synthesis of Cisapride. Cisapride, a prokinetic agent previously used to treat gastrointestinal motility disorders, relies on precisely structured organic molecules for its therapeutic action.

The synthetic route to Cisapride typically involves coupling this piperidine derivative with other chemical moieties. The stereochemistry and functional groups present in Ethyl cis-4-amino-3-methoxypiperidine-1-carboxylate are integral to constructing the final Cisapride molecule with the correct three-dimensional arrangement, which is crucial for its biological activity. The requirement for high purity (≥98%) in this intermediate ensures that the synthesis proceeds efficiently and that the resulting Cisapride API meets all necessary quality and safety standards.

The pharmaceutical manufacturing sector places immense importance on reliable sourcing of such intermediates. Companies involved in the synthesis of Cisapride, or related research, depend on suppliers who can consistently provide Ethyl cis-4-amino-3-methoxypiperidine-1-carboxylate monohydrochloride with the specified purity and correct chemical identity. Proper storage, as per industry recommendations, is also a key factor in maintaining the compound's efficacy for its intended use.

While Cisapride's therapeutic use has been restricted in many regions due to safety concerns, the intermediate itself remains valuable for research purposes and in regions where it may still be utilized or studied. The knowledge gained from synthesizing and working with such compounds contributes to the broader field of medicinal chemistry, informing the development of new therapeutic agents with improved safety profiles and efficacy. The continued availability of high-quality intermediates like Ethyl cis-4-amino-3-methoxypiperidine-1-carboxylate supports ongoing pharmaceutical innovation.